Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.…
Fulgent Genetics (FLGT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Fulgent Genetics (NASDAQ: FLGT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 1,315 employees.
The shares were at 24.12 USD on 20 November 2026, down 8.5% over 52 weeks. Its 52-week range is 13.46 USD to 31.04 USD: the price is 22.3% below the high and 79.2% above the low.
Its market capitalisation is 673.89M USD.
Fulgent Genetics reports return on equity of -5.4%, an operating margin of -37.1% and revenue up 7.5% year over year.
It holds more cash than debt, a net cash position of 282.37M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Hold; their mean price target of 25.00 USD is 3.6% above the current price. The next earnings report is expected on 26 February 2027.